Real Human Fat Ex vivo to unravel human adipose tissue complexity

Our patented breakthrough ExAdEx technology overcomes the barriers of human adipose tissue culture for therapeutic and testing purposes. ExAdEx technology relies on the innate ability of human adipose tissue stem cells to proliferate in response to mechanical stimuli, within a native extracellular matrix that acts as a 3D bioactive support.
From donor-derived human adipose tissue biopsies, ExAdEx technology stimulates a subpopulation of actively proliferating adipose stem cells to expand within native endogenous 3D mini-tissue units retaining full matrix structure, vascular and lymphatic networks.
For the very first time, ExAdEx technology preserves the full native adipose tissue structure and environment to provide long-term viable and fully competent human adult vascularized adipose tissue organoids for drug development, dermo-cosmetic and nutraceutical research.

EXADEX

in vitro human testing platform

A unique research and testing platform of 3D in vitro models of human adipose tissue to support original claims for cosmetic and nutraceutical ingredients and investigate physiological and pathological mechanisms of action for drug development and drug screening against obesity and chronic metabolic diseases.

OBADEX

An innovative tissue therapy approacH

Our innovative cell therapy approach of metabolically active adipose tissue to answer the unmet medical need of patients suffering from obesity and chronic metabolic diseases
(type-2 diabetes, cardiovascular diseases, NAFLD and NASH) who do not have any tailored therapeutic solution.

Our partners and Supporters

NEWS & UPDATE

ExAdEx attending IMCAS 2024

ExAdEx-Innov at IMCAS World Congress 2024

ExAdEx-Innov will ATTEND IMCAS WORLD CONGRESS 2024 WITH SPEAKERS AT 3 DIFFERENT SESSIONS IMCAS World Congress is the leading congress in dermatology, plastic surgery and

KOL on adipose tissue biology.

Research Director (DR1 INSERM).
Team Leader of « Stem Cells and Differentiation » Lab at Institut de Biologie Valrose (Nice). 

Label of Laboratoire d’Excellence by the French National Research Agency (Investissements pour le Futur, Labex Signalife program). 

Co-inventor of 5 patents

Expert in clinical applications of adipose tissue.

Plastic Reconstructive and Aesthetic Surgeon in Nice.

Member of the Medical Council of Alpes Maritimes region.

Expert for the French National Regulatory Agency ANSM for medical devices.

Certified by French Health Autority HAS (2020-2024).

PhD thesis (2018) on fat tissue and adipose tissue stem cells grafting.

Expert in cell therapy and immunology. 

Senior Lecturer (Maitre de conférences).

Responsible of the Cell and Gene Therapy Unity of Nice University Hospital (CHU de Nice).

Director of « Micoralis » research team at Université Côte d’Azur (Nice).

Founder and CEO of the biotech company Biointerférence (2003-2006).

Co-inventor of 5 patents.

Vincent is responsible of company strategy and technological innovation, thanks to his double skill set in science and deeptech startup development.

With a deep knowledge and vision about ExAdEx technology, Vincent has actively worked as a deeptech entrepreneur to push further the development of breakthrough innovative products around human adipose tissue, which lead him to create ExAdEx-Inov. 

In addition to his entrepreneurial skills, Vincent has a strong background in biology (PhD in Cellular and Molecular Biology from Université Côte d’Azur) and training in clinical research management (CRA training at the Faculty of Medicine of La Timone, Marseille). 

He is co-inventor of the 2 company’s patent families. 

Main areas of expertise: DeepTech entrepreneur; Bioengineering of human adipose tissue. 

Luigi is responsible of the management of company operations and business development strategy, thanks to his expertise in biotech startup development.

With a double competence and training in business and science (including an MBA from IAE Paris Sorbonne Business School and a PhD in Cytological Sciences from Rome University La Sapienza), Luigi has been managing business development and R&D projects in a preclinical CRO and a biotech startup company in previous years. 

He has been supporting ExAdEx-Innov project and business development since his position as an Entrepreneur in Residence for CNRS Innovation Tech Transfer Office in 2021.

Main areas of expertise: Biotech Startup Business Development; Project management